Enhancement of dissolution rate of class II drugs (Hydrochlorothiazide); a comparative study of the two novel approaches; solid dispersion and liqui-solid techniques  by Khan, Amjad et al.
Saudi Pharmaceutical Journal (2015) 23, 650–657King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEEnhancement of dissolution rate of class II drugs
(Hydrochlorothiazide); a comparative study of the
two novel approaches; solid dispersion and
liqui-solid techniques* Corresponding author.
E-mail address: zafar_iqbal@upesh.edu.pk (Z. Iqbal).
1 Tel.: +92 91 9239619; fax: +92 91 9218131.
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jsps.2015.01.025
1319-0164 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Amjad Khan, Zafar Iqbal *,1, Yasar Shah, Lateef Ahmad, Ismail, Zia Ullah,
Aman UllahDepartment of Pharmacy, University of Peshawar, Peshawar 25120, PakistanReceived 30 December 2014; accepted 28 January 2015






Similarity factorAbstract Liqui-solid technique and solid dispersion formation are two novel approaches for enhance-
ment of dissolution rate of BCS class II drugs. Liqui-solid compact converts a liquid drug or drug solu-
tion into a free ﬂowing powder with enhanced dissolution rate. In case of solid dispersion drug is
molecularly dispersed in a hydrophilic polymer in solid state. In the present study, Liqui-solid and solid
dispersion techniques were applied to enhance the dissolution of the Hydrochlorothiazide. Three
formulations of Hydrochlorothiazide were prepared by liqui-solid technique using micro crystalline cel-
lulose as carrier material and colloidal silicon dioxide as coating material. Water, poly ethylene glycol-
400 and Tween-60 were used as solvent system. Solid dispersions of Hydrochlorothiazide were prepared
by solvent fusion method using PEG-4000 as carrier polymer. Tablets were subjected to evaluation of
various physical and chemical characteristics. Dissolution proﬁles of tablets prepared by the novel tech-
niques were compared with marketed conventional tablets. Model independent techniques including
similarity factor, dissimilarity factor and dissolution efﬁciency were applied for comparison of dissolu-
tion proﬁles. The results obtained indicated that liqui-solid compact formulations were more effective in
enhancing the dissolution rate compared with solid dispersion technique. The liqui-solid compacts
improved the dissolution rate up to 95% while the solid dispersion increased it to 88%.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dissolution behavior of an active pharmaceutical ingredient
(API) from a dosage form is determined by its solubility
(Ali, 2005). Nearly 40% of new APIs are poorly water-soluble
and lower dissolution rate of the compact solid dosage form is
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Poor water soluble drugs require more time to dissolve in the
gastrointestinal ﬂuid under normal conditions that may delay
the absorption of the drug to the systemic circulation
(Kavitha et al., 2011). Various approaches as salt formation,
size reduction, complexation, microencapsulation and solid
dispersion have been applied to improve poor dissolution rate
of water insoluble drugs (Appa et al., 2010; Sanjeev and
Ravindra, 2010). Solid dispersion systems using hydrophilic
polymers have signiﬁcantly improved the dissolution rate as
the drug is dispersed in matrix at molecular level (Ashok and
Prabhakar, 2012). Manufacturing problems associated with
solid dispersions, such as the use of excessive organic solvents
and poor physical characteristics of dosage form development
have been overcome using self-emulsifying and surface-active
agents supports (Cherukuri et al., 2012). Solid dispersions
are dispersion of the API in an inert carrier or a matrix in
the solid state. Concept of solid dispersion was introduced ﬁrst
by Sekiguchi and Obi in 1961 (Appa et al., 2010; Tyagi and
Dhillon, 2012). Obi and Sekiguchi showed that the eutectic
mixture of sulfathiazole and physiologically inert water soluble
carrier, urea, exhibited an improved absorption and excretion
after oral administration compared with single sulfathiazole.
The drug may be dispersed at the molecular level in the amor-
phous or crystalline matrices. Solid dispersions are prepared
by the melt process, solvent process or a melt-solvent method
(Santhosh et al., 2011). Supercritical ﬂuid technology has been
recently applied in the preparation of solid dispersions.
Dispersions obtained by the melting process are often called
Melts and those obtained by the solvent method are often
referred to as co precipitates or co evaporates. Solid dispersion
improves the dissolution rate of the drug due to the extremely
small particle size, solubilizing effect of the hydrophilic
carrier, an excellent wettability and dispersibility of the drug
particles in GIT and the formation of metastable polymorphs.
In addition to improving bioavailability, recently solid
dispersion systems are being considered for sustained release
dosage forms. The only difference between the two uses of
solid dispersions is the use of the carrier with different proper-
ties. Another new technique for improving the dissolution rate
of poor water soluble drugs is the liqui-solid technique. This
technique is to turn a liquid into a free ﬂowing powder, appar-
ently dry and compressible (Vijay et al., 2011). The liquid may
be a liquid drug, a drug solution or drug dispersion in a non-
volatile solvent that is adsorbed on the porous carrier material
by physical mixing (Varshney and Chatterjee, 2012). Liquid
carriers commonly used are water-miscible organic solvent
with a high boiling point such as poly ethylene glycol,
propylene glycol and glycerin. Support system is composed
of a porous material such as micro crystalline cellulose (Sahil
et al., 2011).
Liqui-solid compacts improve the wetting properties and
surface area available for dissolution. Liqui-solid technique is
a low cost, simple and economical method that can be easily
applied commercially. It requires minimal excipients and is less
technical compared to other techniques such as improving
dissolution by solid dispersions and microencapsulation
(Yousef et al., 2007). Formulation of a high dose of lipophilic
drug is the main limitation of the solid–liquid technique.
Larger dose drugs require large amount of liquid vehicle for
the formation of the solution resulting larger amount of carrier
and coating material, required to obtain a free ﬂowing powder.This will increase the compression weight of the tablet and will
cause problems during administration. Hydrochlorothiazide
(HCTZ) is a BCS class II drug with poor water solubility
and good permeability. Its molecular weight is 297.74 g/mol.
It is commonly used as an antihypertensive agent and as diure-
tic (Panneer et al., 2010).
In current study two methods have been studied for
enhancement of dissolution rate of HCTZ i.e.
 Liqui-solid technique.
 Solid dispersion technique.
Different formulations were prepared by the two techniques
and evaluated for various ofﬁcial and un-ofﬁcial parameters.
The formulations prepared by the two techniques were com-
pared with each other and with the commercially available
conventional tablets of HCTZ.2. Material and methods
2.1. Material
Model drug Hydrochlorothiazide (HCTZ), was received as a
kind gift from Ferozsons Laboratories Pvt. Ltd. Nowshera,
Pakistan. Rest of the excipients (PEG-400, PEG-4000, Micro
crystalline cellulose, colloidal silicon dioxide, magnesium stea-
rate, cross linked carboxy methyl cellulose sodium) were pur-
chased from local market. All the materials were of
pharmaceutical grade and were used as received.
2.2. Instrumentation
Digital balance (Precisa, Switzerland), double cone mixer
(Morgan Instruments) and rotary compression machine (ZP-
21, China) were used during tablet preparation. Pharma Test
set of instruments (Pharma Test, Germany) consisting of hard-
ness and thickness tester, disintegration apparatus and dissolu-
tion apparatus were used for physical analysis of the tablets.
HPLC system used for analysis consisted of pump (series-
200), online degasser (series-200) Peltier column oven (series-
200) and UV/visible detector (series-200).n.
2.3. Methods
2.3.1. Determination solubility of drug in various non-volatile
solvents
The solubility of the Hydrochlorothiazide was determined
using three different solvent systems i.e. Poly ethylene glycol
(PEG-400), PEG-400 + water and PEG-400 + water +
Tween-60 at 25 C and was calculated by Eq. (1).
Solubility ¼ Amount of HCTZ ðmgÞ
Volume of solvent ðmlÞ ð1Þ2.3.2. Stability of drug in nonvolatile solvent system
The stability of the drug in the solvent system was determined
using clear glass bottle with screw cap at 45 ± 2 C (75%
R.H.) for 10 days. Drug content of the solution was deter-
mined on 1, 5 and 10 day in triplicate. The drug content, color
and odor were evaluated during the speciﬁed period.
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Liqui-solid compacts were designed on the basis of mathemati-
cal models proposed by Yousef et al. (2007). On the basis of
drug solubility poly ethylene glycol 400 (PEG-400), water
and Tween-60 was selected as liquid vehicle. Micro crystalline
cellulose was used as carrier material and colloidal silicon





Where R= Excipients ratio; Q=Weight of carrier and
q=Coating material.
The liquid load factor was determined by dissolving the
drug in nonvolatile solvent system (PEG-400 + water +
Tween 60). Drug solution was then loaded to carrier material
and blended with coating material. Liquid load factor was cal-




Where W=Weight of liquid medication and Q=Weight of
carrier material.
2.3.4. Preparation of tablet on the basis of Liqui-solid technique
Drug was dispersed in solvent system by gently heating at
40 ± 2 C with constant stirring until uniform dispersion
was formed. Drug dispersion was slowly incorporated into car-
rier material with continuous blending for 15 min. The mixer
was then paused for 10 min for complete adsorption of drug
into core of the powder. Disintegrant and lubricant were
added to the admixture and blended for further 3 min. Same
procedure was used for preparation of all the formulations
of liquid solid compacts.
All the formulations of liqui-solid compacts were com-
pressed using rotary compression machine (ZP-21, China) ﬁt-
ted with 13.5 mm round shallow concave punches having
bisection line. Compression weight of the tablets was
500 mg/tablet.Table 1 Composition of liqui-solid compacts.
Formulation code Solvent system Carrier material
LSC-01 PEG+ Tween 60 +Water M.C. Cellulose
LSC-02 PEG+ Tween 60 +Water M.C. Cellulose
LSC-03 PEG+ Tween 60 +Water M.C. Cellulose
M.C. Cellulose; micro crystalline cellulose.
Table 2 Composition of tablets prepared using solid dispersion.
Ingredients SD-01 SD-02
Hydrochlorothiazide 6.25 6.25
Polyethylene glycol 4000 6.25 12.50
Micro crystalline cellulose 12.50 12.50
Tablettose-80 70.50 64.25
Cross carmellose sodium 3.00 3.00
Magnesium stearate 1.50 1.50
Ethyl alcohol Q.S. Q.S.
Quantities are given as %w/w.2.3.5. Preparation of solid dispersion
Solid dispersion of HCTZ was prepared using fusion–solvent
method (Santhosh et al., 2011). HCTZ and PEG-4000 were
accurately weighed. HCTZ was dissolved in methanol and
PEG-4000 was melted on a water bath. Drug solution was
added to molten PEG-4000 slowly and stirred vigorously.
Solvent was evaporated by heating on water bath. The residue
was then dried in desiccators for 24 h and granulated through
mesh number 20 (see Table 1).
2.3.6. Preparation of tablets on the basis of solid dispersion
technique
Solid dispersion of HCTZ and PEG-4000 was mixed with dilu-
ents, lubricant and disintegrant, the composition of the
formulation is shown in Table 2. All the materials, except
lubricant, were sifted through mesh number 30 and blended
in a laboratory scale double cone mixer for 5 min at 25 rpm.
Lubricant was passed through mesh number 60, added to rest
of the blend and blended for 2 min. The granules were com-
pressed into tablets using rotary compression machine (ZP-
21, China) ﬁtted with 9.5 mm round biconcave punches.
Compression weight of the tablets was 200 mg/tablet.
2.3.7. Post compression evaluation of tablets
2.3.7.1. Physical parameters of tablets. Weight variation of the
tablets was performed as per United States Pharmacopoeia
(USP-35/NF30, 2012).
Thickness of the tablets was measured using digital tablet
hardness and thickness tester (Pharma Test, Germany).
Thickness of 20 tablets from each formulation was measured
and results were presented as Mean ± S.D.
The crushing strength of the tablets (n= 10) was measured
using digital tablet hardness and thickness tester (Pharma Test,
Germany) and their mean was calculated.
Friability of the tablets was determined according to
United States Pharmacopoeia (USP-35/NF30, 2012), using
Rosch friabilator (Faisal Engineering, Pakistan).
Disintegration time of the tablets (n= 6) was determined
according to USP (USP-35/NF-30, 2012) using puriﬁed water
held at 37 ± 2 C as disintegration medium.Liquid drug concentration Liquid load factor Unit dose (mg)
10% w/w 0.50 12.50
15% w/w 0.33 12.50









Table 3 Solubility of HCTZ in various solvents.
Solvent system Solubility (mg/ml)
PEG-400 2.53
PEG-400 + water (50:50) 1.88
PEG-400 + water (75:25) 6.49
PEG-400 + water (25:75) 2.71
PEG-400 + water + Tween-60 7.18
PEG; poly ethylene glycol.






Day-1 100.30 ± 0.74 Un aﬀected Un aﬀected
Day-5 101.12 ± 0.29 Un aﬀected Un aﬀected
Day-10 100.80 ± 0.35 Un aﬀected Un aﬀected
Results of drug content are presented as Mean ± S.D. (n= 3).
Enhancement of dissolution rate of class II drugs 6532.3.7.2. Determination of drug content. Drug content of the
tablets was determined according to USP (USP-35/NF-30,
2012) using HPLC system. HPLC system was controlled by
Perkin–Elmer Totalchrom Workstation Software (version
6.3.1). Phosphate buffer (0.1 M) and acetonitrile (9:1; pH
3.0) were used as mobile phase.
2.3.7.3. In vitro drug release study. Dissolution rate of the
tablets was determined according to USP using apparatus-1
at 100 rpm (USP-35/NF-30, 2012). Dissolution media con-
sisted of 900 ml of 0.1 N HCl held at 37 ± 2 C. Sample
(5 ml) was withdrawn at speciﬁed time intervals (0, 5, 15, 30,
45 and 60 min), ﬁltered and analyzed for amount of drug
released using HPLC.
2.3.8. Comparison of dissolution rate
Model independent approach was applied for comparison of
dissolution proﬁles. Dissolution proﬁle of two types of
formulation was compared on the basis of their similarity fac-
tor (f2), dissimilarity factor (f1) and dissolution efﬁciency
(D.E.). These parameters were determined for tablets from
optimal formulation of both the novel techniques, compared
with each other and marketed conventional tablets of
HCTZ. Dissimilarity factor was calculated using Eq. (4)
(Paulo and Jose, 2001; Bashar et al., 2010) and similarity factor





f2 ¼ 50 logf½1þ ð1=nÞ
X
ðRt TtÞ20:5  100g ð5Þ
Where Rt =Dissolution rate of standard product at time ‘‘t’’
and Tt =Dissolution rate of test product at time t.
The ‘‘f2’’ value of 50 or greater ensures sameness or equiva-
lence of the two curves and also the performance of the two
products.
Dissolution efﬁciency is the percentage of the area of rec-
tangle described by 100% dissolution. It was calculated
according to the following equation;
D:E: ¼ y dt
Y100  T 100 ð6Þ
where D.E. = Dissolution efﬁciency; y=Amount of drug
released in time ‘‘t’’; Y100 = 100 percent drug released and
T= Total time.
Dissolution efﬁciency was calculated for optimal formula-
tions of both the novel techniques and marketed product at
30 min and 60 min. Along with various parameters given
above comparison of amount of drug released within initial
30 min (Q30min) and maximal drug released within 60 min
(Q60min) was also made.
3. Results and discussions
3.1. Solubility of HCTZ in different nonvolatile solvent systems
According to Biopharmaceutical classiﬁcation system, HCTZ
is a class II drug, practically insoluble in water and its reported
water solubility is 0.70 mg/ml (Rashmi et al., 2011). The maxi-
mum solubility of HCTZ in PEG-400 was 2.53 mg/ml; theaddition of water increased the solubility. In PEG:water
(3:1), the solubility of HCTZ was increased to 6.50 mg/ml
and further increase in water reduced the solubility. The addi-
tion of Tween-60 further increased the solubility as shown in
Table 3. Maximum solubility (7.18 mg/ml) was observed in
solvent system consisting of PEG-400 + water + Tween-60
and was selected for preparation of liqui-solid compacts.
3.2. Drug stability in non-volatile solvent system
Nonvolatile solvent system selected on the basis of solubility
for preparation of liquid solid compacts was composed of
PEG-400, water and Tween-60. Drug was dissolved in solvent
system up to maximum and subjected to stress condition
(45 ± 5 C and 75 ± 5% R.H.) for ten days. Drug solution
was analyzed at day-1, day-5 and day-10 for chemical and
physical stability. The data showed that drug was stable in
the selected non-volatile solvent system under the stress condi-
tions for 10 days, results are depicted in Table 4. Similarly no
changes were observed in physical appearance, color and odor
of the samples. These results indicate the physical and chemical
stability of the HCTZ in the selected solvent system.
3.3. Postcompression evaluation of liqui-solid compacts
3.3.1. Physical parameters of liqui-solid compacts
Physical parameters of the tablets include physical appearance,
weight variation, mechanical strength, disintegration behavior
and drug content. Mechanical strength of the tablets was esti-
mated by crushing strength and friability. Disintegration
behavior of the tablets was evaluated by disintegration time
determined according to USP (USP-35/NF-30, 2012).
Compression weight of liqui-solid compacts was 500 mg
and tablets were compressed on 13.5 mm round shallow con-
cave punches. Physically surface of all the tablets was smooth
and shiny without any sticking and picking. The highest weight
variation observed was ±3.70% (Table 5) which is within the
ofﬁcial range of ±7.50% (USP-35/NF-30, 2012). Low weight
Table 5 Postcompression evaluation of liqui-solid compacts.












LSC-01 ±3.70 81.69 ± 0.83 4.71 ± 0.53 0.3 99.31 ± 0.09 479 ± 39
LSC-02 ±2.98 79.21 ± 1.03 4.38 ± 0.10 0.48 98.19 ± 0.62 388 ± 47
LSC-03 ±3.53 94.77 ± 1.29 4.55 ± 0.38 0.45 99.17 ± 0.39 395 ± 61
Results are presented as Mean ± S.D.
a n= 10.
b n= 3.
654 A. Khan et al.variation conﬁrms uniform ﬂow of the material during com-
pression which was expected to be retarded by liquid
medication.
Crushing strength of tablets (n= 10) randomly selected
from each formulation, was in the range of 78–96 Newton.
The data show that tablets are hard enough to resist stress dur-
ing handling and transportation.
Friability for all the formulations was within the ofﬁcial
range (USP-35/NF-30, 2012). Capping and edging were not
observed in any formulation. Inclusion of liquid medication
in tablets improved the mechanical strength of tablets prepared
by liqui-solid compacts. Strong interlocking produced by liq-
uid component and low porosity may be responsible for higher
crushing strength of tablets.
Disintegration time of tablets from all the formulations was
within the ofﬁcial (USP-35/NF-30, 2012). Disintegration rate
of the liquid solid compacts was expected to be higher due
to the presence of organic solvents. Organic solvents tend to
enhance compressibility of the tablets by the formation of
hydrogen bonds and strong mechanical interlocking (De
Jong, 1987). Tablets with high compressibility have high crush-
ing strength and slow disintegration due to lower porosity.
PEG-400 is water soluble and does not retard tablet disintegra-
tion. The presence of cross linked carboxy methyl cellulose
sodium and Tween-80 further contributed to rapid disintegra-
tion. CCNa is a super disintegrant, expends to larger extant by
water absorption resulting in rapid tablet disintegration and
was used in same concentration (3%) in all formulations.
Drug content of all the formulations was in the range of 98–
102% of the claimed quantity as shown in Table 5. Uniform
drug content conﬁrms proper mixing of drug with rest of the
excipients.
3.3.2. Postcompression evaluation of tablet prepared by solid
dispersion
Solid dispersion containing tablets was compressed on
9.50 mm round shallow concave punches at compression
weight of 200 mg/tablet. The weight variation was within the
ofﬁcial limits and highest observed value was ±3.09%.
Compared to liqui-solid compact their weight variation was
very low.
Crushing strength of the tablets was in the range of 80–
105 N. Highest crushing strength was observed for SD-01
(103.41 N ± 0.97) that may be due to small quantity of
PEG-4000 in the formulation and Tablettose-80 constituted
most of its bulk. Tablettose-80 is a smart excipient having very
good ﬂow and compressibility. It contributed to higher crush-
ing strength of the tablets and in the present formulations it
constituted the major bulk of the tablets. Thickness of thetablet was within the range of 3–4 mm. Almost all the formula-
tions had same thickness irrespective of their composition.
Friability of all the tablets was within the ofﬁcial limits
(USP-35/NF-30, 2012). Tablets from all the formulations were
smooth and shiny without any sticking and picking. PEG has
good lubrication activity and binding action. Due to the rea-
son all the formulations containing solid dispersion had better
mechanical strength as compared to liqui-solid compacts.
Drug content of tablets was determined in triplicate for
twenty tablets, randomly selected from each formulation.
Drug content for all the formulations was within the range
of 99–102% of the claimed quantity.
3.3.3. In vitro drug release
Dissolution rate of HCTZ was studied for both types of
formulations (USP-35/NF30, 2012) using 900 ml 0.1 N HCl
as dissolution media maintained at 37 ± 2 C. Results of
dissolution rate were presented up to 60 min. The dissolution
rate of the marketed conventional tablets was within the ofﬁ-
cial limits (USP-35/NF-30, 2012) however, the drug release
was slow and only 64.02% was released in 60 min. During ini-
tial 15 min only 19% of the drug was released and Q50% was
not achieved during initial 30 min.
Signiﬁcant increase in dissolution rate was observed with
liquid solid compacts. Maximally, 95.38% drug was released
in 60 min (LSC-01). During initial 30 min more than 70% of
the drug was released. Smallest drug release during initial
30 min was 62.06 showing that Q50% was successfully achieved
within initial 30 min (Fig. 1).
Concentration of drug in liquid medication has a signiﬁcant
effect on enhancement of dissolution rate. Highest drug release
obtained in terms of both rate and extent of drug release when
10% drug concentration in liquid vehicle was used. Maximum
drug release was achieved in 60 min when used 10% drug con-
centration in liquid vehicle as shown in Fig. 1. At lower con-
centration (10%) most of the drug particles dissolve in liquid
system and may present in molecular form that may enhance
rate and extent of drug dissolution.
Similarly at higher drug concentration in liquid system,
most of the drug remains in dispersed form and ratio of the
dissolved particles is lower so the dissolution rate is relatively
lower than that of the low drug concentration. Tween-60 is a
surfactant and improves wettability that may also have con-
tributed to the enhanced dissolution rate.
In solid dispersion drug and polymers come in close contact
with each other at molecular level. Dissolution rate of poor
water soluble drug is improved by enhanced drug water inter-
action. PEG-4000 is water soluble and improves wettability of
the drug to a greater extent. Dissolution rate of HCTZ
Figure 1 Dissolution proﬁle of liqui-solid compacts.
Figure 3 Comparison of amount of drug released during initial
30 min (Q30min). M. Tablet; marketed conventional tablet,
LCS-01; optimal formulation prepared by liqui-solid compact,
SD-05; optimal formulation containing solid dispersion.
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used in 1:1 (drug to polymer ratio) the maximum release was
65.79% in 60 min and Q50% was not achieved during initial
30 min.
Best dissolution proﬁle was obtained when PEG-4000 was
used in drug to polymer ratio of 1:6 (SD-05). 88.63% drug
was released in 60 min and Q50% was achieved within 15 min
(see Fig. 2).
Dissolution rate of liqui-solid compacts and solid disper-
sion was compared with marketed product at 30 min and
60 min. After 30 min 48.27% drug was released from marketed
tablets. Its Q50% was not achieved during initial 30 min. In case
of both the novel techniques more than 70% drug was released
during initial 30 min. Drug release during initial 30 min was
higher for liqui-solid compacts as compared to solid disper-
sion, as shown in Fig. 3. 78.29% drug was released for liqui-
solid compacts while 74.34% drug was released from tablets
prepared by solid dispersion. 3.95% more drug released by
liqui-solid compacts in comparison with solid dispersion.
Amount of dissolved drug in liqui-solid compact system is
responsible for higher drug release. When drug concentration
in liquid component was increased, amount of dissolved drug
reduced and drug was present as dispersion. It resulted in
reduced drug release. Formulations of liqui-solid compactsFigure 2 Dissolution proﬁle of tablets containing solid
dispersion.containing 15% and 20% of drug in liquid medium had
Q30min lower than that of formulation containing 10% drug
(see Fig. 4).
Comparison of dissolution proﬁles of liqui-solid compacts
and solid dispersion showed that maximum drug release was
observed with liqui–solid system. In liqui–solid system
95.38% (n= 3) of drug was released in 60 min. In case of solid
dispersion system 88.63% drug was released in 60 min. Both
the novel techniques exhibited a marked increase in maximum
release of HCTZ from tablets, as shown in Fig. 5. With tablets
prepared by direct compression, 64% of the drug was released
maximally while with liqui-solid the percentage was 95.38%
and 88.63% with solid dispersion.
Comparison of the two novel techniques showed that liqui-
solid compact released 6.80% more drug as compared to solid
dispersion. Its dissolution efﬁciency was also higher during ini-
tial 30 min (39.14%). It proved that liqui-solid compact was
more efﬁcient than solid dispersion.3.3.4. Comparison of dissolution proﬁles
Comparison of dissolution proﬁles of conventional marketed
tablets prepared by direct compression and those prepared
by the two novel techniques are presented in Fig. 5.Figure 4 Comparison of maximum drug released in 60 min
(Q60min).
Figure 5 Comparison of dissolution proﬁle of marketed product
and optimal formulations. Marketed tablet; conventional tablets
available in market, LCS-01; liqui-solid compacts, SD; solid
dispersion.
Table 7 Dissolution efﬁciency at various points.
Formulation code Dissolution eﬃciency
30 min 60 min
Marketed tablet 24.14 64.02
LSC-01 39.14 95.38
SD-01 37.17 88.63
Data have been rounded off to two digits after decimal point.
LSC-01; optimal formulation of liqui-solid compacts.
SD-01; optimal formulation of tablets containing solid dispersion.
Table 8 Similarity (f2) and dissimilarity factor (f1) of dissolu-
tion proﬁle.
Formulation f1 f2
Liqui-solid Compact 81.75 27.50
Solid dispersion 70.38 37.35
Data have been rounded off to two digits after decimal point.
656 A. Khan et al.Signiﬁcant increase was observed in dissolution proﬁle with the
two novel techniques.
3.3.4.1. Comparison of dissolution efﬁciency. Dissolution efﬁ-
ciency is commonly applied for comparison of dissolution pro-
ﬁles to decide better one. Dissolution efﬁciency was calculated
using equation-6, for optimal formulations prepared by the
two novel techniques and marketed product at 30 min and
60 min. At 30 min dissolution efﬁciency of the marketed pro-
duct was 24.14% which increased to 64.02% at 60 min.
Dissolution efﬁciency of liqui-solid compact was 39.14% at
30 min and at 60 min became 95.38%. Dissolution efﬁciency of
the two novel techniques was higher as compared to marketed
conventional tablets. At 30 min dissolution efﬁciency of liqui-
solid compact was 1.62 times of the marketed product.
Similarly at 60 min, it was 1.49 times. Higher dissolution efﬁ-
ciency at both the points indicated that liqui-solid compact
has signiﬁcantly enhanced dissolution rate (see Table 6).
Solid dispersions had dissolution efﬁciency of 37.17%
which is 1.54 times of the marketed product. Ratio of dissolu-
tion efﬁciency at 60 min was 1.38 times.
From the data presented in Table 7, it was evident that both
the novel techniques had improved dissolution efﬁciency
throughout the dissolution proﬁle. In comparison with solid
dispersion, liqui-solid technique was more efﬁcient. Its dissolu-
tion efﬁciency was higher at both the points from that of solidTable 6 Postcompression evaluation of tablets containing solid dis






SD-01 ±2.41 103.41 ± 0.97 3.4
SD-02 ±2.77 82.33 ± 1.10 3.5
SD-03 ±3.09 96.59 ± 0.38 3.5
SD-04 ±2.58 89.22 ± 0.13 3.6
SD-05 ±2.96 90.08 ± 0.62 3.6
Results are presented as Mean ± S.D.
Data have been rounded off to two digits after decimal point.
a n= 10.
b n= 3.dispersions. At 30 min, dissolution efﬁciency of liqui-solid
compacts was 5.31% higher than solid dispersion and at
60 min it was 7.62% higher.
Dissolution efﬁciency improved directly with amount of liq-
uid medication. Higher dissolution efﬁciency was exhibited at
both test points (30 min and 60 min) by formulations of high
liquid load factor. When amount of liquid is high drug is avail-
able in the solution form and adsorbed at molecular level on
the carrier surface. Adsorption of molecular drug results in
improved dissolution efﬁciency.
3.3.4.2. Dissimilarity factor (f1) and similarity factor (f2) of
dissolution proﬁles. Dissolution proﬁle of the tablets prepared
by both the novel techniques was compared with that of mar-
keted product separately by applying similarity factor (f2) and
dissimilarity factor (f1). Dissolution proﬁle of both the novel
techniques was signiﬁcantly different from that of the mar-
keted product. Both the techniques showed very low similarity
factor and high dissimilarity factor, proving that dissolution
proﬁles are different.
In case of liqui-solid compacts, the difference from dissolu-
tion proﬁle of marketed tablets was more prominent. Liqui-
solid compact exhibited lower values of similarity factor









2 ± 0.37 0.45 99.23 ± 0.09 398 ± 25
7 ± 0.20 0.31 101.06 ± 0.08 391 ± 41
1 ± 0.19 0.49 101.37 ± 0.31 386 ± 34
9 ± 0.21 0.62 100.79 ± 0.11 395 ± 46
5 ± 0.31 0.3 99.54 ± 0.41 391 ± 54
Enhancement of dissolution rate of class II drugs 657high (81.75) as compared to that of solid dispersion. Values of
‘‘f1’’ and ‘‘f2’’ proved that as compared to solid dispersion
dissolution proﬁle of liqui-solid compacts was more different
from dissolution proﬁle of marketed product. It had improved
dissolution rate of HCTZ effectively than solid dispersion.
4. Conclusion
The study showed that both the novel techniques enhanced
dissolution rate of HCTZ to a larger extent when compared
with conventional tablet in terms of dissolution efﬁciency,
similarity factor and dissimilarity factor. Dissolution efﬁciency
of the novel techniques has increased by 40% in comparison
with conventional tablets.
Liqui-solid technique was observed to be more effective in
enhancing rate and extent of drug release. Due to a large vari-
ety of hydrophilic polymers smaller tablets with improved
dissolution rate and better physical characteristics can be
obtained by solid dispersion technique.
Excipients used in formulation of liqui-solid compact and
solid dispersions were commonly used in pharmaceutical
industries. All of the excipients are economical and will not
affect cost of the ﬁnal product to a larger extent.
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